Page tree
Skip to end of metadata
Go to start of metadata


This trial seeks to determine the effect of androgen deprivation therapy with or without docetaxel on overall survival in prostate cancer patients with EXTENSIVE metastatic disease (visceral lesions or 4+ bony metastases) and who have been on androgen deprivation therapy for less than 90 days.



Johns Hopkins Hospital

Principal investigator:

Michael Carducci, M.D.

  • No labels